US biotech, CAMP4 Therapeutics, has secured US$100m in a Series B financing round that it says will be used to accelerate expansion of its regulatory RNA (regRNA) platform.
Ncardia and Horizon Discovery have partnered to provide custom, genetically-modified and differentiated human cells for drug discovery and preclinical models.
A study published by graduate students at MIT showed that a synthetic mRNA-based ‘programming language’ can control protein expression in gene therapy.
Lonza has inked a biologics deal with Denali to make neurodegenerative disease therapies, offering the Californian firm opportunity to have production “on their back doorstep.”
Is plastic fantastic? Is stainless still à la mode*? Do Chinese hamsters continue to tow the cell line? Biopharma-Reporter wants your opinions for its second annual biomanufacturing survey.
Selexis and Xencor have entered into a strategic agreement which strengthens an existing relationship for multi-specific antibody cell line development
The US Department of Defense has developed a portable, on-demand biopharmaceutical production system that could be used in warzones to make treatments at point-of-care.
Dyadic has agreed to sell its enzyme-producing fungal expression system and the rest of its industrial technology business to DuPont for $75 million (€70 million).
Outsourcing-pharma.com presents a roundup of contract manufacturing news with deals for Lonza, DSM and Ark Therapeutics and an expanded agreement with Shire for AMRI.
Catalent Pharma Solutions and German expression system developer Cevec Pharmaceuticals have partnered to create a cell development service that, they claim, will help drugmakers generate stable lines faster.
ISCO’s stem cell manufacturing facility has passed final building inspection, enabling it to implement the processes and cGMP standards needed to produce clinical-grade products.
Agilent and Millipore have formed a collaboration to develop fully validated chromatin immunoprecipitation (ChIP) microarray kits that will improve productivity and streamline epigenetic analysis.
Celera Genomics have filed an Investigational New Drug (IND)
application for a novel histone deacetylase (HDAC) inhibitor that
has proved effective in inhibiting cancer cell proliferation. The
filing also signifies Celera's transformation...
Hamilton Life Science Robotics has taken Invitrogen's Gateway
Technology one step further by creating an automated cloning system
that monitors and tracks each plate undergoing various processes.
The system aims to further refine...
